TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, taking place in Miami, FL from June 9-11, 2025. Michael S. Weiss, the company's Chairman and CEO, will engage in a fireside chat on Tuesday, June 10, 2025, at 10:40am ET. Investors and interested parties can access a live webcast of the discussion through the Events page in the Investors & Media section of TG Therapeutics' website at http://ir.tgtherapeutics.com/events.

Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46^th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively.   For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When is TG Therapeutics (TGTX) presenting at the Goldman Sachs Healthcare Conference 2025?

TG Therapeutics will present on Tuesday, June 10, 2025, at 10:40am ET through a fireside chat.

Who will represent TG Therapeutics (TGTX) at the Goldman Sachs Healthcare Conference?

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will represent TG Therapeutics at the conference.

Where can I watch TG Therapeutics' (TGTX) presentation at the Goldman Sachs conference?

The presentation can be viewed via live webcast on the Events page within the Investors & Media section of TG Therapeutics' website at http://ir.tgtherapeutics.com/events.

Where is the Goldman Sachs Healthcare Conference 2025 being held?

The conference is being held in Miami, FL from June 9-11, 2025.